57032 Federal Register / Vol. 69, No. 184 / Thursday, September 23, 2004 / Notices 

FEDERAL RESERVE SYSTEM

Notice of Proposals to Engage in 

Permissible Nonbanking Activities or 

to Acquire Companies that are 

Engaged in Permissible Nonbanking 

Activities

The companies listed in this notice 

have given notice under section 4 of the 

Bank Holding Company Act (12 U.S.C. 

1843) (BHC Act) and Regulation Y (12 

CFR Part 225) to engage de novo, or to 

acquire or control voting securities or 

assets of a company, including the 

companies listed below, that engages 

either directly or through a subsidiary or 

other company, in a nonbanking activity 

that is listed in § 225.28 of Regulation Y 

(12 CFR 225.28) or that the Board has 

determined by Order to be closely 

related to banking and permissible for 

bank holding companies. Unless 

otherwise noted, these activities will be 

conducted throughout the United States.

Each notice is available for inspection 

at the Federal Reserve Bank indicated. 

The notice also will be available for 

inspection at the offices of the Board of 

Governors. Interested persons may 

express their views in writing on the 

question whether the proposal complies 

with the standards of section 4 of the 

BHC Act. Additional information on all 

bank holding companies may be 

obtained from the National Information 

Center website at www.ffiec.gov/nic/.

Unless otherwise noted, comments 

regarding the applications must be 

received at the Reserve Bank indicated 

or the offices of the Board of Governors 

not later than October 8, 2004.

A. Federal Reserve Bank of New 

York (Jay Bernstein, Bank Supervision 

Officer) 33 Liberty Street, New York, 

New York 10045–0001:

1. Community Bank System, Inc., 

Dewitt, New York; to engage de novo

through its subsidiary Benefit Plans 

Administrative Services, Inc., Utica, 

New York, in employee benefits 

consulting and incidental activities, 

pursuant to section 225.28(b)(9)(ii) of 

Regulation Y.

Board of Governors of the Federal Reserve 

System, September 17, 2004.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. 04–21363 Filed 9–22–04; 8:45 am]

BILLING CODE 6210–01–S

FEDERAL RESERVE SYSTEM

Notice of Proposals to Engage in 

Permissible Nonbanking Activities or 

to Acquire Companies that are 

Engaged in Permissible Nonbanking 

Activities

The companies listed in this notice 

have given notice under section 4 of the 

Bank Holding Company Act (12 U.S.C. 

1843) (BHC Act) and Regulation Y (12 

CFR Part 225) to engage de novo, or to 

acquire or control voting securities or 

assets of a company, including the 

companies listed below, that engages 

either directly or through a subsidiary or 

other company, in a nonbanking activity 

that is listed in § 225.28 of Regulation Y 

(12 CFR 225.28) or that the Board has 

determined by Order to be closely 

related to banking and permissible for 

bank holding companies. Unless 

otherwise noted, these activities will be 

conducted throughout the United States.

Each notice is available for inspection 

at the Federal Reserve Bank indicated. 

The notice also will be available for 

inspection at the offices of the Board of 

Governors. Interested persons may 

express their views in writing on the 

question whether the proposal complies 

with the standards of section 4 of the 

BHC Act. Additional information on all 

bank holding companies may be 

obtained from the National Information 

Center website at www.ffiec.gov/nic/.

Unless otherwise noted, comments 

regarding the applications must be 

received at the Reserve Bank indicated 

or the offices of the Board of Governors 

not later than October 8, 2004.

A. Federal Reserve Bank of New 

York (Jay Bernstein, Bank Supervision 

Officer) 33 Liberty Street, New York, 

New York 10045–0001:

1. Community Bank System, Inc., 

Dewitt, New York; to engage de novo

through its subsidiary Benefit Plans 

Administrative Services, Inc., Utica, 

New York, in employee benefits 

consulting and incidental activities, 

pursuant to section 225.28(b)(9)(ii) of 

Regulation Y.

Board of Governors of the Federal Reserve 

System, September 20, 2004.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. 04–21405 Filed 9–22–04; 8:45 am]

BILLING CODE 6210–01–S

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request

AGENCY: Agency for Healthcare Research 

and Quality, HHS.

ACTION: Notice.

SUMMARY: This notice announces the 

intention of the Agency for Healthcare 

Research and Quality (AHRQ) to request 

the Office of Management and Budget 

(OMB) to allow the proposed 

information collection project: 

‘‘Voluntary Customer Surveys Generic 

Clearance for the Agency for Healthcare 

Research and Quality’’ (formerly known 

as Voluntary Customer Satisfaction 

Survey Generic Clearance for the 

Agency for Healthcare Research and 

Quality). In accordance with the 

Paperwork Reduction Act of 1995, 44 

U.S.C. 3506(c)(2)(A), AHRQ invites the 

public to comment on this proposed 

information collection request to allow 

AHRQ to conduct customers surveys. 

This proposed information collection 

was previously published in the Federal 

Register on July 13, 2004 and allowed 

60 Days for public comment. No public 

comments were received. The purpose 

of this notice is to allow an additional 

30 Days for public comment.

DATES: Comments on this notice must be 

received by October 25, 2004.

ADDRESSES: Written comments should 

be submitted to: John Kraemer, at the 

Office of Information and Regulary 

Affairs, OMB at the following e-mail 

address JohnlKraemer@omb.eop.gov

and the fax number is (202) 395–6974.

FOR FURTHER INFORMATION CONTACT:

Cynthia D. McMichael, AHRQ, Reports 

Clearance Officer, (301) 427–1651.

SUPPLEMENTARY INFORMATION: 

Proposed Project 

‘‘Voluntary Customer Surveys Generic 

Clearance for the Agency for Healthcare 

Research and Quality.’’

In response to Executive Order 12862, 

the Agency for Healthcare Research and 

Quality (AHRQ) plans to conduct 

voluntary customer surveys to assess 

strengths and weaknesses in agency 

program services. Customer surveys to 

be conducted by AHRQ may include 

readership surveys from individuals 

using AHRQ automated and electronic 

technology databases to determine 

satisfaction with the information 

provided or surveys to assess effect of 

the grants streamlining efforts.

Federal Register / Vol. 69, No. 184 / Thursday, September 23, 2004 / Notices 57033

Results of these surveys will be used 

in future program planning initiatives 

and to redirect resources and efforts, as 

needed, to improve AHRQ program 

services. The current clearance will 

expire September 30, 2004. This is a 

request for a generic approval from 

OMB to conduct customer surveys over 

the next three years. 

Method of Collection 

The data will be collected using a 

combination of methodologies 

appropriate to each survey. These 

methodologies include: 

• Evaluation forms; 

• Mail surveys; 

• Focus groups; 

• Automated and electronic 

technology (e.g., e-mail, Web-based 

surveys, instant fax, AHRQ Publications 

Clearinghouse customer feedback) and, 

• Telephone surveys.

ESTIMATED ANNUAL RESPONDENT BURDEN

Type of Survey No. of

respondents 

Average burden/response Total hours of 

burden 

Mail/telephone surveys ................................................................................................................ 51,200 .15 7,680 

Automated/Web-based ................................................................................................................ 52,000 D.163 8.476 

Focus groups ............................................................................................................................... 200 1.0 200 

Totals .................................................................................................................................... 103,400 NA 16,356 

Request for Comments 

In accordance with the above cited 

Paperwork Reduction Act legislation, 

comments on the AHRQ’s information 

collection are requested with regard to 

any of the following: (a) Whether the 

proposed collection of information is 

necessary for the proper performance of 

functions of AHRQ, including whether 

the information will have practical 

utility; (b) the accuracy of the Agency’s 

estimate of the burden (including hours 

and costs) of the proposed collection of 

information; (c) ways to enhance the 

quality, utility, and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information on 

respondents, including the use of 

automated collection techniques or 

other forms of information technology. 

Comments submitted in response to 

this notice will summarized and 

included in the request for OMB 

approval of the proposed information 

collection. All comments will become a 

matter of public record.

Dated: September 16, 2004. 

Carolyn M. Clancy, 

Director.

[FR Doc. 04–21339 Filed 9–22–04; 8:45 am] 

BILLING CODE 4160–90–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES

Food and Drug Administration

[Docket No. 2004N–0408]

Regulatory Site Visit Training Program

AGENCY: Food and Drug Administration, 

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug 

Administration’s (FDA’s) Center for 

Biologics Evaluation and Research 

(CBER) is announcing the initiation of a 

Regulatory Site Visit Training Program. 

This program is intended to give CBER’s 

regulatory review staff, compliance staff, 

and other relevant staff an opportunity 

to visit biologics facilities. The visit is 

intended to provide first hand 

experience to CBER staff and to give a 

better understanding of the biologics 

industry, including its challenges and 

its operations. The purpose of this 

notice is to invite biologics companies 

interested in participating in this 

program to contact CBER for more 

information.

DATES: Submit a written or electronic 

requests for participation in this 

program by October 25, 2004.

ADDRESSES: If your biologics facility is 

interested in offering a site visit or 

learning more about this training 

opportunity for CBER staff, you should 

submit a request to participate in this 

program to the Division of Dockets 

Management (HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852. Submit 

electronic requests to http://

www.fda.gov/dockets/ecomments.

FOR FURTHER INFORMATION CONTACT:

Lonnie Warren-Myers, Division of 

Manufacturers Assistance and Training, 

Center for Biologics Evaluation and 

Research (HFM–49), Food and Drug 

Administration, 1401 Rockville Pike, 

suite 200N, Rockville, MD 20852–1448, 

301–827–2000, FAX: 301–827–3079, email: 

cbertrainingsuggestions@cber.fda.gov.

SUPPLEMENTARY INFORMATION:

I. Background

CBER regulates biological products 

including blood and blood products, 

vaccines, and cellular and gene 

therapies. CBER is committed to 

advancing the public health through 

innovative regulations that help ensure 

the safety, effectiveness, and timely 

delivery to patients of biological 

products. CBER has initiated various 

training and development programs to 

promote high performance of its 

regulatory review staff, compliance staff, 

and other relevant CBER staff. CBER 

seeks to continuously enhance and 

update review efficiency and quality as 

well as the quality of its regulatory 

efforts and interactions. CBER is 

initiating the Regulatory Site Visit 

Training Program to provide CBER staff 

the opportunity to visit biologics 

facilities to observe first-hand the 

industry’s biologic development and 

manufacturing processes and thereby 

obtain better understanding of the 

biologics industry and its operations.

Further, this program is intended to 

improve CBER’s understanding of 

current practices, regulatory impacts 

and needs, and improve communication 

between CBER staff and industry. The 

first phase of the program will focus on 

blood, plasma, and fractionation 

industries including transfusion centers, 

although other industries may be 

considered including vaccines, cellular 

and gene therapy, and tissues.

II. The Regulatory Site Visit Training 

Program

A. Regulatory Site Visits

In this program, over a period of time 

to be agreed upon with the biologics 

facility, small groups (five or less) of 

CBER staff may observe operations of 

biologics manufacturing, packaging, 

pathology/toxicology laboratory testing, 

and regulatory affairs operations. These 

visits, or any part of the program, are 

not intended as a mechanism to inspect, 

assess, judge, or perform a regulatory 

enforcement function, but are meant to 

improve mutual understanding and to